1Wild S,Roglic G,Green A,et al.Global prevalence of diabetes:estimates for the year 2000 and projections for 2030.Diabetes Care,2004,27:1047-1053.
2Yang W,Lu J,Weng J,et al.Prevalence of diabetes among men and women in China.N Engl J Med,2010,362:1090-1101.
3Sarwar N,Gao P,Seshasai SR,et al.Diabetes mellitus,fasting blood glucose concentration,and risk of vascular disease:a collaborative meta-analysis of 102 prospective studies.Lancet,2010,375:2215-2222.
4Fox CS,Coady S,Sorlie PD,et al.Increasing cardiovascular disease burden due to diabetes mellitus:the Framingham Heart Study.Circulation,2007,115:1544-1550.
5Yusuf S,Hawken S,Ounpuu S,et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):case-control study.Lancet,2004,364:937-952.
6American diabetes association.Standards of medical care in diabetes-2008.Diabetes Care,2008,31(Suppl 1):S12-S54.
7Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation,2002,106:3143-3421.
8Buse JB,Ginsberg HN,Bakris GL,et al.Primary prevention of cardiovascular diseases in people with diabetes mellitus:a scientific statement from the American Heart Association and the American Diabetes Association.Circulation,2007,115:114-126.
9Larosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med,2005,352:1425-1435.
10Baigent C,Keech A,Kearney PM,et al.Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet,2005,366:1267-1278.
4Litwin M, Sladowska J, Syczewska M,et al. Different BMI cardiovascular risk thresholds as markers of organ damage and metabolic syndrome in primary hypertension. Pediatr Nephrol, 2008,23(5 ) : 787-796.
5Litwin M, Sladowska J, Antoniewicz J, et al. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens, 2007,20( $ ) : 875-882.
6Gupta R, Guptha S. Strategies for initial management of hypertension. Indian J Med Res, 2010,132 ( 5 ) : 531-542.
7Kazim SF, Shahid M. Losartan associated anaphylaxis and angioneurotic oedema. J Pak Med Assoc, 2010,60( 8 ) : 685-686.
8Numata T, Miyatake N, Wada J, et al. Comparison of serum uricacid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract,2008,80( 1 ) :el-eS.
9Niskanen L, Laaksonen DE, Lindstram J, et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the finnish diabetes prevention study. Diabetes Care, 2006,29(3) :709-711.
10Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol, 2003,18(6) :523-530.
